|
IL248243B2
(en)
|
2014-04-10 |
2024-04-01 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Defined composition gene modified t-cell products
|
|
EP3149044B1
(en)
*
|
2014-06-02 |
2020-10-21 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Chimeric antigen receptors targeting cd-19
|
|
US10738116B2
(en)
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
|
WO2017027291A1
(en)
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
|
WO2017070042A1
(en)
|
2015-10-20 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing t cell populations using akt inhibitors
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
CN105906720A
(zh)
*
|
2016-05-16 |
2016-08-31 |
武汉汉密顿生物科技股份有限公司 |
靶向性嵌合抗原受体修饰的免疫细胞及其制备方法和应用
|
|
CN105949324B
(zh)
*
|
2016-06-30 |
2019-08-27 |
上海恒润达生生物科技有限公司 |
靶向gpc3的嵌合抗原受体及其用途
|
|
CN105949325B
(zh)
*
|
2016-07-08 |
2019-07-16 |
重庆精准生物技术有限公司 |
包含cd27胞内结构域的嵌合抗原受体、慢病毒载体及其应用
|
|
JP7160482B2
(ja)
|
2016-09-02 |
2022-10-25 |
レンティジェン・テクノロジー・インコーポレイテッド |
Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
CN107936120B
(zh)
*
|
2016-10-13 |
2021-03-09 |
上海赛比曼生物科技有限公司 |
Cd19靶向性的嵌合抗原受体及其制法和应用
|
|
CN118406655A
(zh)
*
|
2017-01-10 |
2024-07-30 |
普瑞赛格恩公司 |
通过新基因开关表达系统调节多肽的表达
|
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
WO2018209324A2
(en)
|
2017-05-11 |
2018-11-15 |
The Broad Institute, Inc. |
Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
CA3062506A1
(en)
*
|
2017-05-12 |
2019-05-23 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
AU2018269194B2
(en)
|
2017-05-15 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors and their uses
|
|
CN110997920A
(zh)
|
2017-06-07 |
2020-04-10 |
英特拉克森公司 |
新型细胞标签的表达
|
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
WO2019030757A1
(en)
*
|
2017-08-09 |
2019-02-14 |
Ctg Pharma Ltd. |
CHIMERIC ANTIGEN RECEPTOR FOR HER2 / NEU AND LYMPHOCYTES T THE EXPRESSANT
|
|
US12043870B2
(en)
|
2017-10-02 |
2024-07-23 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
WO2019075055A1
(en)
|
2017-10-11 |
2019-04-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
JP7080514B2
(ja)
|
2017-12-22 |
2022-06-06 |
アブクロン・インコーポレイテッド |
悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
CA3090512A1
(en)
|
2018-02-09 |
2019-08-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Tethered interleukin-15 and interleukin-21
|
|
EP3757133A4
(en)
|
2018-02-11 |
2021-12-01 |
Jiangsu Hengrui Medicine Co., Ltd. |
ISOLATED ANTIGENIC CHEMICAL RECEPTOR, MODIFIED T LYMPHOCYTE INCLUDING IT AND ASSOCIATED USE
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
EP3790629A1
(en)
*
|
2018-05-11 |
2021-03-17 |
CRISPR Therapeutics AG |
Methods and compositions for treating cancer
|
|
IL321548A
(en)
|
2018-05-22 |
2025-08-01 |
Immunitybio Inc |
Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
CN108841792A
(zh)
*
|
2018-06-14 |
2018-11-20 |
浙江大学 |
靶向cd19和ebna1基因修饰的t细胞及其制备方法与应用
|
|
CN108864307A
(zh)
*
|
2018-07-23 |
2018-11-23 |
北京多赢时代科技有限公司 |
信号肽优化靶向cd19的嵌合抗原受体、表达该嵌合抗原受体的t细胞及制备方法和应用
|
|
CN110819678A
(zh)
*
|
2018-08-07 |
2020-02-21 |
上海恒润达生生物科技有限公司 |
一种评估cart细胞有效性的方法
|
|
AU2019344795A1
(en)
*
|
2018-09-17 |
2021-03-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors targeting CD19 and CD20 and their uses
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
TW202031894A
(zh)
|
2018-11-01 |
2020-09-01 |
中國大陸商亘喜生物科技（上海）有限公司 |
用於t細胞工程之組合物及方法
|
|
CN111253487B
(zh)
*
|
2018-12-03 |
2024-02-02 |
广东东阳光药业股份有限公司 |
Cd19抗体及其应用
|
|
CN120005921A
(zh)
|
2018-12-12 |
2025-05-16 |
凯德药业股份有限公司 |
嵌合抗原和t细胞受体及使用的方法
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
CN109734813B
(zh)
|
2019-01-28 |
2022-06-17 |
广东昭泰体内生物医药科技有限公司 |
一种嵌合抗原受体及其应用
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
RU2742000C2
(ru)
*
|
2019-03-13 |
2021-02-01 |
Общество С Ограниченной Ответственностью "Анабион" |
Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор
|
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
SG11202112032WA
(en)
*
|
2019-04-30 |
2021-11-29 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
AU2020270298A1
(en)
|
2019-05-07 |
2021-12-23 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Engineered immune cell targeting BCMA and use thereof
|
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
|
KR20220026586A
(ko)
*
|
2019-06-27 |
2022-03-04 |
크리스퍼 테라퓨틱스 아게 |
암 치료를 위한 키메라 항원 수용체 t세포 및 nk세포 억제제의 용도
|
|
CA3144875A1
(en)
*
|
2019-06-27 |
2020-12-30 |
Byoung S. Kwon |
Chimeric antigen receptor with 4-1bb costimulatory domain
|
|
US20220249565A1
(en)
*
|
2019-06-27 |
2022-08-11 |
Eutilex Co., Ltd. |
Chimeric antigen receptor with 4-ibb costimulatory domain
|
|
CN110305849B
(zh)
*
|
2019-08-01 |
2021-03-30 |
广东万海细胞生物科技有限公司 |
稳定表达car的t细胞及其制备方法与应用
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
AU2020382219A1
(en)
*
|
2019-11-13 |
2022-05-12 |
Crispr Therapeutics Ag |
Manufacturing process for making T cells expressing chimeric antigen receptors
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
AU2021357520A1
(en)
|
2020-03-05 |
2022-09-29 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
CA3191211A1
(en)
|
2020-09-08 |
2022-03-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell phenotypes associated with response to adoptive cell therapy
|
|
EP4243937A2
(en)
|
2020-11-13 |
2023-09-20 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
|
|
CA3202218A1
(en)
|
2020-12-18 |
2022-06-23 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
WO2022147444A2
(en)
|
2020-12-30 |
2022-07-07 |
Alaunos Therapeutics, Inc. |
Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
|
|
WO2022165419A1
(en)
|
2021-02-01 |
2022-08-04 |
Kyverna Therapeutics, Inc. |
Methods for increasing t-cell function
|
|
WO2022180586A1
(en)
*
|
2021-02-25 |
2022-09-01 |
Senthil Natesan |
Car t-cell product and method of preparation thereof
|
|
US20240124942A1
(en)
|
2021-02-26 |
2024-04-18 |
Fundació Institut De Recerca Contra La Leucèmia Josep Carreras |
Markers of prediction of response to car t cell therapy
|
|
US20230046228A1
(en)
*
|
2021-07-26 |
2023-02-16 |
Crispr Therapeutics Ag |
Methods for manufacturing genetically engineered car-t cells
|
|
CA3228773A1
(en)
*
|
2021-08-12 |
2023-02-16 |
Gaurav KHARYA |
Chimeric antigen receptors (car) for b cell malignancies
|
|
US20240342282A1
(en)
|
2021-08-13 |
2024-10-17 |
Ludwig-Maximilians-Universität München |
Anti-csf1r car expressing lymphocytes for targeted tumor therapy
|
|
TWI863006B
(zh)
*
|
2021-10-18 |
2024-11-21 |
美商凱特製藥公司 |
用於嵌合抗原受體之信號傳導域
|
|
CN119156224A
(zh)
|
2021-12-31 |
2024-12-17 |
美国政府(由卫生和人类服务部的部长所代表) |
接种疫苗的t细胞疗法作为针对癌症的联合免疫疗法
|
|
US20230210900A1
(en)
|
2022-01-04 |
2023-07-06 |
Kyverna Therapeutics, Inc. |
Methods for treating autoimmune diseases
|
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
EP4598949A1
(en)
|
2022-10-07 |
2025-08-13 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
AU2024213852A1
(en)
|
2023-01-30 |
2025-07-03 |
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) |
Anti-cd86 car expressing lymphocytes for targeted tumor therapy
|
|
AU2024230609A1
(en)
|
2023-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Cell therapy for treating systemic autoimmune diseases
|
|
WO2024249954A1
(en)
|
2023-05-31 |
2024-12-05 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025049631A1
(en)
*
|
2023-08-28 |
2025-03-06 |
Kyverna Therapeutics, Inc. |
Allogeneic car-t cell therapies and manufacture thereof
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
US20250144234A1
(en)
|
2023-11-02 |
2025-05-08 |
Capstan Therapeutics Inc. |
RNA for In vivo Transfection with Increased Expression
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025129201A1
(en)
|
2023-12-15 |
2025-06-19 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025160480A1
(en)
|
2024-01-26 |
2025-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
|
|
US20250302763A1
(en)
|
2024-02-22 |
2025-10-02 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025250587A1
(en)
|
2024-05-29 |
2025-12-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Drug-regulatable, inducible cytokine expression
|